SCHEMBL97980

SCHEMBL97980

CCOC(=O)C(Cc1ccc(OC)c2c1ccc(=O)n2C)C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
TSHR P16473 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
CYP19A1 P11511 4/20 0.39
NQO2 P16083 4/20 0.39
KMT2A Q03164 2/20 0.38
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
MAPT P10636 1/20 0.34
HPGD P15428 2/20 0.34
TNF P01375 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.33
BLM P54132 1/20 0.33
GLA P06280 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97855 0.88 CYP19A1 (0.38) ALDH1A1TSHRSMN1; SMN2CYP19A1NQO2
SCHEMBL97251 0.86 L3MBTL1 (0.40) ALDH1A1TSHRSMN1; SMN2CYP19A1NQO2
SCHEMBL98644 0.79 KMT2A (0.46) ALDH1A1TSHRCYP19A1NQO2KMT2A
SCHEMBL98162 0.78 CYP19A1 (0.39) ALDH1A1TSHRSMN1; SMN2CYP19A1NQO2
SCHEMBL98475 0.78 CYP19A1 (0.37) ALDH1A1CYP19A1NQO2KMT2ARXFP1
SCHEMBL98053 0.76 CYP19A1 (0.36) ALDH1A1TSHRSMN1; SMN2CYP19A1NQO2
SCHEMBL490730 0.73 ALDH1A1 (0.48) ALDH1A1TSHRSMN1; SMN2KMT2ALMNA
SCHEMBL96811 0.72 KMT2A (0.38) ALDH1A1TSHRCYP19A1NQO2KMT2A
SCHEMBL96460 0.72 MAPT (0.54) ALDH1A1SMN1; SMN2CYP19A1NQO2KMT2A
SCHEMBL132509 0.70 CYP19A1 (0.40) ALDH1A1TSHRSMN1; SMN2CYP19A1NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 ALDH1A1 2458/4885TSHR 110/4885SMN1; SMN2 3084/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 ALDH1A1 2458/4885TSHR 110/4885SMN1; SMN2 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.